Want to join the conversation?
$CME's cash and cash equivalents was $1.2Bil at June 30, 2015, down from $1.4Bil at Dec. 31, 2014. A majority of cash and cash equivalents balance is invested in money market mutual funds that invest only in US Treasury securities or US government agency securities. $CME's exposure to credit and liquidity risk is minimal on investment nature.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.